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Résumé en
anglais
The purpose of this study was to develop different injectable nanosized drug delivery
systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule
(PNC) encapsulating apigenin (AG) and compare their characteristics to identify the
nanovector(s) that can deliver the largest quantity of AG while being biocompatible.
Two liposomes with different surface characteristics (cationic and anionic), a LNC and
a PNC were prepared. A novel tocopherol modified poly(ethylene glycol)-b-
polyphosphate block-copolymer was used for the first time for the PNC preparation.
The NDDSs were compared by their physicochemical characteristics, AG release,
storage stability, stability in serum, complement consumption and toxicity against a
human macrovascular endothelial cell line (EAhy926). The diameter and surface
charge of the NDDSs were comparable with previously reported injectable
nanocarriers. The NDDSs showed good encapsulation efficiency and drug loading.
Moreover, the NDDSs were stable during storage and in fetal bovine serum for
extended periods, showed low complement consumption and were non-toxic to
EAhy926 cells up to high concentrations. Therefore, they can be considered as
potential injectable nanocarriers of AG. Due to less pronounced burst effect and
extended release characteristics, the nanocapsules could be favorable approaches for
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